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Abstract
The use of medicines to treat attention deficit/hyperactivity disorder (ADHD) has increased worldwide, including the use 
of amphetamine-based medicines or prodrugs that metabolise to amphetamine in vivo. At the same time, drugs-of-abuse 
testing by non-specific, point-of-care immunoassay methods (‘quick tests’) has increased. This article discusses the risk of 
‘false positive’ results or post-analytical misinterpretations of results when immunoassays are used to analyse biological 
samples from ADHD patients. A rapid evidence review was conducted to identify studies that have focused on the risk of 
‘false positive’ test results in immunoassay testing of patients treated with atomoxetine, bupropion, clonidine, guanfacine, 
methylphenidate, and modafinil. There is only evidence to suggest that bupropion should cause ‘false positive’ immuno-
assay results. However, there is a lack of systematic, updated evaluations and validations of cross-reactivity patterns for 
immunoassays in the literature. Advanced laboratory methods can distinguish the use of medicines from illicit amphetamine 
by stereospecific analysis of dextro- and levoamphetamine; however, these analytical services are not commonly available 
for routine drug testing. The present situation calls for more awareness, proper education and information on these critical 
ethical issues in drug testing, both for clinicians, other healthcare professionals involved in drug testing and for patients in 
medical treatment for ADHD. The pitfalls of immunoassays due to cross-reactivity and insufficient specificity/sensitivity can 
have serious negative consequences for patients safety with regard to incorrect laboratory drug-testing results. Consequently, 
confirmatory laboratory analysis should always be performed for ‘presumptive’ positive immunoassay screening results.
Keywords Attention deficit/hyperactivity disorder · Drug testing · Immunoassay · False positive · Public health ethics
Introduction
Worldwide attention deficit/hyperactivity disorder (ADHD) 
affects 4–8% of children and 3–5% of adults worldwide 
(Fayyad et al. 2007; Giacobini et al. 2014) many of whom 
receive pharmacological treatment. A Swedish register-
based study found that 80% of patients with an ADHD diag-
nosis received at least one prescription for ADHD medica-
tion (Giacobini et al. 2014). During the last two decades, 
the medical use of stimulants to treat ADHD has increased 
worldwide (Karlstad et al. 2016; van den Ban et al. 2010). 
At the same time, the use of immunoassays (‘quick tests’) 
for screening of drug use has increased considerably, par-
ticularly in the USA with an overall 14,000-fold increase and 
for general practice a 8700-fold increase during 2000–2009 
(Collen 2012). However, this increase may even be under-
estimated as the data originate from specific procedural 
codes used to bill the United States Medicare and private 
insurance for medical procedures. We assume that this is a 
global trend; however, to our knowledge there is an absence 
of systematic registration of the use of immunoassays for 
point-of-care drug testing in most countries.
Due to the rise in both the (often lifelong) use of ADHD 
medications and the general use of drug testing, they are a 
population with a high prevalence for routine drugs-of-abuse 
testing as part of roadside drug testing to screen drivers 
under the influence of drugs, at emergency departments and 
somatic and psychiatric hospitals where immunoassay test-
ing is used extensively, in military services, in the primary 
health sector for diagnostic purposes, in prisons, in doping 
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testing, and as part of workplace drug testing. Since ADHD 
is associated with a higher risk of developing substance use 
disorders (Ottosen et al. 2016), drug testing of these patients 
may also be more likely, compared to the general population.
As we will discuss in the following, it is crucial that 
immunoassays are used with the appropriate caution and 
consideration. We will focus our attention to drug testing 
for concurrent use of amphetamine. In this paper, we will 
argue that:
• While the use of immunoassays may have some bene-
fits, they have serious limitations related to risk of ‘false 
positive’ results, the risk of overlooking comorbid sub-
stance use and problems of correct interpretation even by 
healthcare professionals.
• Personnel in charge of handling immunoassays should be 
educated and informed about the proper use of immuno-
assays and most importantly about their limitations.
• Patients should be informed about how their prescribed 
medication may affect screening results.
• ‘Presumptive positive’ screening results should be sys-
tematically followed up by confirmatory testing, in order 
to secure patient safety and to improve decision making.
• More research is needed on patterns of cross-reactivity 
for new immunoassays, and proper clinical evaluations 
should be performed on authentic samples.
Issues with ADHD, sports and doping control for stimulants 
have been reviewed elsewhere (Hickey and Fricker 1999) 
and will not be included in our discussion as doping testing 
procedures are internationally standardised and performed 
with confirmatory methods at laboratories accredited by the 
World Anti-doping Agency. Forensic laboratories may use 
immunoassays for pre-screening purposes, but final results 
are always based on reference methods according to forensic 
toxicology laboratory guidelines.
The potential consequences of drug 
screening with immunoassays: general 
considerations
While there may be good reasons to make rational use of 
immunoassays for various purposes, it is crucial that the 
strengths and limitations of these tests are fully acknowl-
edged. Although immunoassays are relatively inexpensive, 
easy and practical to use, the limitations and intrinsic errors 
of this technique for drug testing have been known for dec-
ades, with numerous, published cases in the literature (Moe-
ller et al. 2008; Reisfield et al. 2009; Saitman et al. 2014). 
Among the pitfalls immunoassays (1) do not identify the 
compounds that cause ‘presumptive positive’ results; (2) 
show ‘false positives’ due to cross reactions with medicines, 
food and drink ingredients or endogenous compounds; (3) 
are seldom documented properly in logbooks data and 
patient’s medical records; (4) do not test for new psychoac-
tive substances; (5) are often used by non-medically trained 
personnel; (6) are poorly understood and difficult to interpret 
even by healthcare professionals; and (7) are not system-
atically followed by confirmatory analysis because proper 
guidelines may not be implemented. However, these draw-
backs are often not realised by the personnel that carry out 
the testing at rehabilitation centres, psychiatric hospitals, 
emergency departments, prisons or in the primary health 
sector (Reisfield et al. 2007a, c). All aspects discussed above 
are valid for testing of various biological matrices: blood, 
urine, oral fluid, sweat, and exhaled breath condensate.
To illustrate our concern, workplace drug testing can be 
used. Even though workplace drug testing in the USA has 
been performed under strict legislation since the late 1980s, 
guidelines and testing procedures have still not been fully 
implemented in many parts of the world including several 
European countries (Pierce 2012).
Confirmatory analysis
It is an essential principle that final ‘positive’ drug-test-
ing results should be confirmed in a laboratory with gas 
or liquid chromatography coupled to mass spectrometry 
(GC–MS, LC–MS). These analytical techniques, which are 
used extensively in forensic and clinical toxicology, provide 
the most accurate and unequivocal results for drug and drug 
metabolite identification and quantification. While a number 
of factors cause ‘false negative’ confirmatory drug-testing 
results, avoidance of ‘false positive’ results is generally 
thought to be of greater importance. ‘False positive’ con-
firmatory results could be caused by various pre-analytical, 
analytical and post-analytical errors caused by the sampler, 
the operator, the apparatus or information technology sys-
tems. However, when errors occur, they are not related to 
the analytical principle of the confirmatory method per se 
(chromatography and mass spectrometry).
Confirmatory analysis often involves shipment of a sam-
ple specimen by mail; hence a delay in time to receive the 
final analytical report must be expected. Therefore, immu-
noassays fulfil the need for point-of-care testing and fast 
results, but too often samples may not be forwarded for con-
firmatory analysis.
When not used with the necessary knowledge and pre-
cautions, immunoassays represent a risk for patient safety 
regarding the correctness of laboratory results. Thus, non-
confirmed immunoassay results can misinform clinicians 
and even cause a risk when drug-testing results are used dur-
ing judicial decisions. Note that the issues discussed here for 
ADHD medicines are very similar to the controversy over 
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urine drug testing in pain management monitoring (McMil-
lin et al. 2013; Reisfield et al. 2007b).
Next we will outline what is known about commonly 
prescribed ADHD medication, the risk of cross-reactivity 
causing ‘false positive’ results when using immunoassays. 
We also discuss potential consequences for both the clinician 
and the patient, when knowledge about how ADHD medica-
tions interact with drug-testing results is limited.
ADHD medication and the risk of ‘false 
positives’ using immunoassays
Today, a range of medications is used to treat ADHD. For 
the purpose of simplicity, we will divide the medications 
into amphetamine-based drugs (e.g. dexamphetamine and 
lisdexamfetamine) and non-amphetamine-based drugs (ato-
moxetine, bupropion, clonidine, guanfacine, methylpheni-
date and modafinil). As we will describe below, it can be 
anticipated that compliant patients treated with ampheta-
mine-based drugs will screen positive for amphetamine on 
immunoassays, while the risk of screening positive when 
treated with non-amphetamine-based drugs may be less 
evident.
‘False positive’ drug screening results for amphetamine 
have also been associated with use of other drugs and herbal 
foods (Baron et al. 2011; Dadlani et al. 2018; Liu et al. 2015; 
Marin et al. 2016; Olsen et al. 1992; Papa et al. 1997; Pav-
letic and Pao 2014; Vorce et al. 2011). This also includes 
case reports for common drugs, e.g. aripiprazole (Kaplan 
et al. 2015) and metformin (Fucci 2012). In addition, meth-
amphetamine is metabolised to amphetamine in vivo and is 
in fact an expected finding after ingestion of this drug.
Drug testing and amphetamine‑based medication
Patients treated with amphetamines or lisdexamfetamine will 
generally have positive screening results for amphetamine 
when using both immunoassays and confirmatory testing, 
except for very dilute urine samples, where the concentration 
may be lower than the confirmatory cutoff level. We believe 
that patients should be informed about this, so they can pre-
pare themselves for potential encounters with drug testing. 
This could be by notifying a future employer beforehand of 
likely test outcomes or carrying with them a certificate for 
medication. This is important, as drugs containing amphet-
amines or drugs metabolising to amphetamine in vivo do 
not reveal this by their common brand names, and therefore 
patients may not be able to foresee their risk status in drug-
testing situations.
It is equally important that the personnel perform-
ing the screening tests on patients treated with amphet-
amine-based ADHD medications knows that a positive 
result should be expected. Also, it is important that they 
acknowledge that it is not possible, from the immunoas-
say technique alone, to discern whether the tested person 
is positive due to administration of licensed medicines or 
illegal amphetamine use or both.
Another important issue relates to whether or not clini-
cians can rely on confirmatory analyses to discern whether 
a positive test result may be caused by use of illegal 
amphetamine drugs. It does remain a challenge for labo-
ratories to distinguish use of legal medicinal drugs from 
drugs of an illegal origin. In the case of amphetamine, 
this would call for chiral (enantiomeric) analysis in order 
to separate the two optical isomers: dextroamphetamine 
[S-(+)-amphetamine, the pharmacologically most active 
enantiomer] and levoamphetamine [R-(−)-amphetamine, 
the less active enantiomer]. Providing evidence whether 
a patient has supplemented a prescribed legal drug dose 
with ‘street-grade’ amphetamine is possible, but interpre-
tation depends on the composition of illegal amphetamine 
found in the specific location (which may not be acces-
sible) and the enantiomeric composition on the drug pre-
scribed in each specific case. If the prescribed drug is pure 
S-(+)-amphetamine, then detection of R-(−)-amphetamine 
(above a certain R/S ratio) may suggest use of ampheta-
mine from an illegal source (Nystrom et  al. 2005). A 
pharmacokinetic study has also shown the applicability 
of enantiomer compositions in the assessment of ‘time 
since dose’ or discrimination between amphetamine from 
pharmaceutical sources and illicit amphetamine (Cody 
et al. 2004).
In cases where an ADHD patient is accused of drug use 
of illicit amphetamine or non-compliance, chiral analysis 
of various matrices may allow for (1) differentiation of the 
use of legal drugs from illicit amphetamine; (2) assess-
ment of non-compliance; and (3) evaluation of self-medi-
cation with illicit amphetamine. However, chiral analysis 
of amphetamines is not a routine in neither clinical nor 
forensic drug testing. It may be difficult to find a labora-
tory to provide this analytical service, not to mention the 
challenge of interpreting such complex data.
Nevertheless, patients and clinicians should be aware 
of the existence of such methodologies for urine, blood or 
hair testing that may be applicable to monitor compliance 
of medication with amphetamine-based medical drugs and 
in some cases also distinguish amphetamine in pharma-
ceutical drugs from illicit amphetamine (Binz et al. 2017). 
Immunoassays for stereospecific analysis of amphetamines 
in urine have been marketed, but these have not been criti-
cally evaluated, and we do not advice to use the products. 
On the contrary, clinicians should contact biochemistry 
laboratories for guidance on the best choice of analyti-
cal services and expertise in post-analytical interpreta-
tion of results, and laboratory personnel in charge of drug 
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testing must be committed to carry out this task in order 
to improve ADHD patients’ safety.
Drug testing and non‑amphetamine‑based 
medication
In this section, we will turn to a discussion of the non-
amphetamine-based drugs. As mentioned, these include 
methylphenidate, which is among the most commonly pre-
scribed medical drugs used to treat ADHD in both children, 
adolescents and adults (Giacobini et al. 2014).
We conducted a rapid evidence review in PubMed the 
16th of March 2018, in order to identify any studies that 
reported on ‘false positive’ amphetamine immunoassay 
screening results with relation to either atomoxetine, bupro-
pion, clonidine, guanfacine, methylphenidate or modafinil.1
The search returned 44 results of which nine studies were 
relevant. The reference lists of the nine relevant studies were 
also searched, in order to identify any relevant studies that 
could have been missed. In total, we identified one study 
concerning atomoxetine, six studies concerning bupropion, 
and three studies concerning methylphenidate. No studies 
were found concerning clonidine, guanfacine or modafinil. 
The results are summarised in Table 1.
Cross‑reactivity of atomoxetine
We identified one study concerning atomoxetine and ‘false 
positive’ screening results on immunoassays. The study 
was based on a single case report (Fenderson et al. 2013). 
According to the World Health Organization, single case 
studies represent the lowest level of evidence (WHO 2000). 
Single, unexplained events could arise from food ingredi-
ents, herbal medicines, endogenous molecules, other drugs 
or metabolites. Since this single case report has not been 
supported by supplemental studies, and considering that 
atomoxetine is not a new type of medication, at present 
the evidence is insufficient to support a substantial risk of 
screening ‘false positive’ for amphetamines on immunoas-
says in patients treated with atomoxetine. However, in the 
absence of high-quality and systematic studies of potential 
cross-reactivity of atomoxetine on screening instruments, it 
is premature to make final conclusions.
Cross‑reactivity of bupropion
The systematic search identified one review and five original 
studies (see Table 1) that all reported on the cross-reactivity 
of bupropion and its principal metabolites in immunoassays 
for amphetamine. Thus, based on the review of findings, we 
believe that patients treated with bupropion are at high risk 
for being falsely tested positive for amphetamines during 
initial drug screening. Cross-reactivity by immunoassays can 
generally be explained as a signal generated by analytes with 
similarity in chemical structure. In the case of bupropion, 
the alpha-methylphenylamine structure is changed by the 
presence of a chlorine atom on the aromatic ring, an oxo 
group and a bulky tert-butyl radical on the amino group. 
It is not possible to assess the risk of cross-reactivity by 
simple reasoning based on chemical structures. Laboratory 
tests must be performed carefully using drug free matrices 
spiked with reference solutions of drugs and metabolites in 
the concentrations found in authentic samples.
Cross‑reactivity of methylphenidate
In the search, we identified two studies relating to the risk 
of cross-reactivity of methylphenidate in amphetamine drug 
screening. One single study has reported methylphenidate 
as cause of ‘false positive’ amphetamine screening results 
(Manzi et al. 2002). Urine samples, originally screened 
negative for amphetamine, were spiked with a solution 
prepared from crushed tablets containing methylphenidate. 
The spiked samples were retested and found positive at 
the 200 ng/ml concentration level using an immunoassay 
method. In a commentary, this procedure was questioned, as 
it is not a good practice to spike urine samples with solutions 
made from crushed tablets (Breindahl and Hindersson 2012). 
The same year, three commercial oral fluid immunoassays 
for amphetamine were evaluated and no cross-reactivity 
was found for methylphenidate even at high concentrations 
(Souza et al. 2012). The authors regretted this since they 
argued for the need to screen for use of ‘amphetamine-type 
stimulants’ in Brazilian drivers and methylphenidate was 
considered belonging to this drug group. Cross-reactivity 
was in this concept considered as a positive feature, if it in 
fact would take place.
Methylphenidate and its major metabolite (ritalinic acid) 
are not connected by any metabolic pathways to other drugs-
of-abuse, including amphetamine. However, there is a per-
sistent myth that methylphenidate cannot be distinguished 
from amphetamine in drug testing. We find no solid pub-
lished evidence to support that urine samples from patients 
using methylphenidate are at risk for ‘false positive’ testing 
for amphetamine when using immunoassays. As for atomox-
etine, we recommend that high-quality research is conducted 
concerning the risk of cross-reactivity and methylphenidate 
1 Search string used in Pubmed the 16th of March 
2018: ((((((((("Guanfacine"[Mesh] OR guanfacine)) OR 
("Clonidine"[Mesh] OR clonidine)) OR ("Bupropion"[Mesh] OR 
bupropion)) OR ("Atomoxetine Hydrochloride"[Mesh] OR atomox-
etine)) OR ("Methylphenidate"[Mesh] OR methylphenidate))) AND 
(("Substance Abuse Detection"[Mesh]) OR ("Immunoassay"[Mesh] 
OR immunoassay)))) AND (amphetamine).
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treatment. Unfortunately, the biased conclusion by Manzi 
et al. has found its way into the Summary of Product Char-
acteristics (SPCs) for methylphenidate drugs worldwide 
causing further confusion and controversies as this misin-
formation continues to be communicated directly to both 
prescribers and users of the drug causing anecdotes that may 
persist for decades.
In summary, the only non-amphetamine-based drug 
where we have substantial evidence of a risk of ‘false posi-
tive’ results is bupropion. However, when proper confirma-
tory methods are used that are regarded as mandatory in 
urine drug testing (Taskinen et al. 2017), substances such 
as bupropion or methylphenidate will not be mistaken 
for amphetamine or visa versa, nor will they mask use of 
amphetamines (Breindahl and Hindersson 2012). We do, 
however, note that only few studies have looked at the cross-
reactivity between non-amphetamine-based drugs used in 
ADHD treatment and amphetamine screening. In future, we 
recommend that studies should be set up to systematically 
evaluate the issue further, in order to provide more robust 
results, from which guidelines can be developed.
Lack of awareness about the fact that the majority of non-
amphetamine-based drugs will not return positive results 
for amphetamine use could have at least two negative con-
sequences. First, patients prescribed with, e.g. methylphe-
nidate may fear being falsely accused of amphetamine drug 
use, which could lead to discontinuation of treatment. One of 
the authors (CMJ) is a board member at the Danish ADHD 
patient organisation and experiences that members specifi-
cally express fear of this. They express being in a dilemma 
about, on the one hand wishing to continue treatment to 
harvest the benefits of the medicine, and on the other hand 
considering discontinuing treatment due to fear of criminali-
sation, false accusations, losing job privileges, etc. Another 
risk is that ‘true positive’ results for amphetamine may be 
misinterpreted and disregarded as being the result of legiti-
mate methylphenidate or atomoxetine treatment, thus poten-
tially overlooking comorbid substance use.
The lack of a valid or updated cross‑reactivity list 
from manufactures
A list of true negative and positive interactions for immu-
noassays would be of benefit in an ideal clinical setting. 
However, it is characteristic for immunoassays in drugs-of-
abuse testing that (1) only a limited number of structure-
related drugs are included in the manufacturer’s valida-
tion, mostly performed on drug free matrices spiked with 
the drugs, but not always with the major metabolites; (2) 
authentic clinical samples may hold concentrations of drugs 
and drug metabolites that are much higher than the specimen 
tested during validation, so that the assay does not func-
tion correctly; (3) even in cases where the manufacturer’s 
lists of cross-reactivity may be comprehensive at the time of 
assay validation (products from the large manufacturers of 
laboratory assays), such lists may not be updated regularly 
with new medical drugs and new psychoactive substances; 
(4) claims of cross-reactivity may not be valid for different 
batches of anti-body based techniques; (5) drug concentra-
tions causing cross-reactivity and positive results depend 
on the cutoff of the assay in a nonlinear manner; and (6) 
although it is clinical relevant that the manufacturers provide 
updated information on the performance of immunoassays, 
we acknowledge that this is a costly and time-consuming 
task, which explains the lack of information from suppliers 
of the numerous products for on-site testing.
The role of the clinical laboratory
Clinical chemists and specialists in laboratory medicine may 
have the best understanding of the limitations of screening 
tests in general, the technical aspects of running such assays 
in a clinical laboratory or in point-of-care testing as well as 
the interpretational elements. However, due to the controver-
sies outlined above a strong professional communication and 
interaction within the networks of patients, clinicians and 
colleagues is essential. Thus, we identify a need for clini-
cal laboratory professionals to step into a more active and 
educational role and be involved in the moral and ethical 
issues of drug screening. It is the potential punitive conse-
quences of ‘presumptive positive’ drugs-of-abuse screening 
results that are the main cause of concern and makes it dif-
ferent from other clinical screening tests. Thus, unexpected 
or unusual drug findings for a patient—also for confirmatory 
results—should always be questioned in search for a correct 
interpretation with full consideration to the patients’ medical 
history and prescription drug list.
Conclusion
While drug testing has its benefits and can be justified in cer-
tain clinical situations, we have outlined some critical, ethi-
cal aspects that needs more attention in both clinical practice 
and research. The risks for ADHD patients of being falsely 
accused of drug abuse or discriminated in cases relating to 
workplace, education, and medical treatment are evident in 
particular for patients who are prescribed amphetamine-
based medications, prodrugs that release amphetamine when 
metabolised and bupropion. On the other hand, knowledge 
about the lack of evidence of cross-reactivity, for example 
for methylphenidate and atomoxetine, is important for those 
who handle the tests, to avoid overlooking potential use 
of non-prescribed amphetamine. We believe that our line 
of argumentation calls for more attention to ensuring that 
patients are educated about their medication. In addition, 
Patients in medical treatment for attention deficit/hyperactivity disorder (ADHD): Are they…
1 3
there is a need to inform professionals who administer 
immunoassays about the patterns of cross-reactivity and 
that all ‘presumptive positive’ screening results should be 
supplemented by confirmatory analysis at a clinical labo-
ratory. With the use of modern laboratory information 
systems, such requisitions should be made automatically. 
Finally, more research, critical evaluation and validation are 
needed to update the current knowledge on immunoassays 
and cross-reactivity with ADHD drugs.
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